Thursday, October 25, 2012
2012-2013 Qualifying Investor Exam Itinerary
* January 19, 2013, 10:00 am CEST: Deadline for completion of 'Qualifying Investor Exam'.
* January 20, 2013: Exam scoring & decision emailed individually by me to exam participants.
* January 21-26, 2013: Funding (investment) payments due- for participation in one-time 30% equity ownership please have a personal/corporate debit/credit card, valid email address, go to http://www.indiegogo.com/projects/243180, review the presentation material and click on the 'contribute now' button; for 100% equity ownership (buyout) please email me at sdoddi11@hotmail.com (preferred) or sdoddi11@yahoo.com for international bank wire transfer details. Kindly note: If a 100% equity ownership (buyout) offer is received in full and good standing, the 30% equity ownership campaign will be cancelled and donations made will not be accepted. For redeeming your donations, you will have to contact Indiegogo by visiting http://www.indiegogo.com/contact/questions and submitting a message to the Indiegogo Customer Happiness Team. THANK YOU.
Sunday, September 23, 2012
Focus
Sjön Therapeutics is involved in development, ownership (by patents), production, and licensing of recombinant adeno-associated virus gene constructs (serotype aav2 and various hybrids) for clinical trials and treatment in the field of human gene therapy. We also offer worldwide human genome sequencing service for screening of disease biomarkers, and certain research and custom order products (see below).
The product portfolio addresses the following human conditions: Lung Cancer [raav2.5p130, raav2.5e1a], Liver Cancer [raav2.3p130, raav2.3e1a], Insulin resistant (type 2) diabetes [raav2acrp30], HIV/AIDS (integrase inhibitor)[raav2;2,5-dkgr], and aav based HIV/AIDS cocktails depending on results of nucleic acid based HIV-1 viral load assay kit (see research below) in early stage, middle stage, and late stage HIV/AIDS.
Please note: For clinical trials and treatment, if not enough virus is used, it will not give 100% of infection. If too much virus is used, it will cause cytotoxicity or other undesired effects. You should use the minimal virus concentration that will give 100% gene delivery. This optimal concentration differs dramatically between cell types. To determine this optimal concentration of virus, you could conduct pilot testing in your system by using marker adenoviruses. For most cell types, viral concentrations of 2 x 10^5 - 1 x 10^6 IFU/PFU (infectious unit)/ml of media gives 100% of infection wthout visible side effects. However, I recommend you test your cell system by using marker viruses.
Exclusive licensing of intellectual property (patents) is available through 'Survivant Consulting LLC' at a cost equivalent to US $210,000 per construct. A viral biosensor is planned.
For further inquiries (customers, physicians, hospitals, healthcare providers) please email sdoddi11@hotmail.com or call +91-9773033833 (leave message).
Thank you
- Mr. Somesh R. Doddi,
Chief Scientist & CEO
Wednesday, July 18, 2012
Additional Information
Product Purity Report- Submit web inquiry (see below).
Clinical Trial Report- Submit web inquiry (see below).
Treatment Protocol- Based on readings; 10^14 IFU/PFU contains 10.2 *10^3 ug. So, every production bottle (5.2*10^12 IFU/PFU) equates to 530ug. At the rate of 10ug/dose, each bottle will last for 53 applications (1 application/day). For a full suggested course of treatment for 48 weeks, approximately 7 production bottles will be required per patient. Question: Is it possible to speed-up the treatment protocol to 265ug/half-bottle/DAY for 14 days (2 weeks) injected into bloodstream (intravenous or intraarterial)? To comment, physicians or others may send a message to sdoddi11@hotmail.com using the email form below.
Subscribe to:
Posts (Atom)